MedPath

Effectiveness of different modalities for high altitude rapid acclimatization

Phase 2
Not yet recruiting
Conditions
Healthy male lowlanders who had not visited high altitude in last 3 years.
Registration Number
CTRI/2022/09/045922
Lead Sponsor
DEFENCE RESEARCH AND DEVELOPMENTAL ORGANIZATION
Brief Summary

Exposure at high altitude (HA) induced hypobaric hypoxia is known to deteriorate health and decrease performance. The aim of the study is to develop of Rapid Acclimatization Schedule for HighAltitude in Western sector using different modalities. 400 volunteers within the age range of 20-40 years will be recruited. The volunteers will be randomized into 4 different groups - Control, Drug treated (Acetazolamide), Stay at Moderate Altitude (Short duration) and Intermittent Hypoxia Exposure (IHE). After recording their baseline parameters at Sea Level area they will be inducted to Stage - I HA by air followed by Stage - II HA by road. In all stages differentphysiological, physical and biochemical parameters would be assessed.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Male
Target Recruitment
200
Inclusion Criteria

a) Age group: 20 – 40 years b) Medical history: SHAPE – I.

Exclusion Criteria

a) Smokers b) Drinker c) Prior induction to HA d) Medical history of any sort.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of Acute Mountain SicknessDuring the initial days after ascent to high altitude area.
Secondary Outcome Measures
NameTimeMethod
Exercise Capacity at High AltitudeAfter 48 and 72 hours after reaching high altitude area.

Trial Locations

Locations (2)

Physiology Laboratory

🇮🇳

JAMMU, & KASHMIR, India

Transit Camp, Chandigarh

🇮🇳

Chandigarh, CHANDIGARH, India

Physiology Laboratory
🇮🇳JAMMU, & KASHMIR, India
Dr Dharmendra Kumar
Principal investigator
9765534896
oichamrcleh@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.